Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518284 · ClinicalTrials.gov registry record · Phase 2
Prevention of Restenosis Following Revascularization
A Phase 2 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00518284 is a Phase 2 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 6 participants.
The verdict
NCT00518284, a Phase 2 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)
Interventions
- DRUG Nanoparticle Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00518284
The ClinicalTrials.gov registry entry for NCT00518284 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nanoparticle Paclitaxel is the first listed.
NCT00518284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00518284 about?
NCT00518284 is a clinical study titled "Prevention of Restenosis Following Revascularization". The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)
What is the current status of trial NCT00518284?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-01. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00518284?
The interventions under investigation include: Nanoparticle Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00518284?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.